AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28760801
Drug: Usual antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual antibiotic treatment with the addition of 8 L of polyethylene glycol (PEG) lavage via nasojejunal tube
Trial: 28760801
Drug: Usual antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual antibiotic treatment
Trial: 19081881
Drug: Plasma-spray and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-spray and small-bead coatings
Trial: 17157114
Drug: Sumatriptan injection
RxNorm normalized name: sumatriptan Injection
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan injection 6 mg
Trial: 14680204
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 10 mg/kg after anaesthetic induction, on bypass, and after protamine at the end of bypass (group B)
Trial: 14680204
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (group A)
Trial: 8804799
Drug: Oral fluconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluconazole, 200 mg once daily
Trial: 8804799
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B, 0.3 mg/kg
Trial: 6541714
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B
Trial: 1733187
Drug: Magnesium gluconate
RxNorm normalized name: Magnesium Gluconate
DrugBank: Magnesium gluconate (DB13749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium gluconate 1 gm orally four times daily
Trial: 6467800
Drug: Nifedipine (rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (rectal infusion at a zero-order rate for 24 hr)
Trial: 31437754
Drug: encorafenib 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Trial: 31437754
Drug: encorafenib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encorafenib 300 mg once daily
Trial: 31437754
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg twice daily
Trial: 29595687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GDPSF and thalidomide
Trial: 25134860
Drug: Strict glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glucose control (90-120 mg/dL)
Trial: 25134860
Drug: Liberal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal glucose control (121-180 mg/dL)
Trial: 9188352
Drug: No-treatment controls
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment controls
Trial: 17592349
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg/kg
Trial: 27052122
Drug: Methimazole therapy
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole therapy in subjects with TSH <1.0 μIU/mL
Trial: 27052122
Drug: Observation (untreated)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation (untreated) in subjects with TSH <1.0 μIU/mL
Trial: 27052122
Drug: Observation (untreated)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation (untreated) in subjects with TSH ≥1.0 μIU/mL
Trial: 24581989
Drug: Daily recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily recombinant FSH
Trial: 24581989
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa and Daily recombinant FSH
Trial: 22415232
Drug: S-1 (80,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80, 100, or 120 mg per day on days 1-28, every 42 days, 4 courses)
Trial: 22415232
Drug: UFT/LV (UFT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/LV (UFT, 300 mg m(‐2) per day as tegafur; LV, 75 mg per day on days 1-28, every 35 days, 5 courses)
Trial: 19458303
Drug: Medihoney Antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medihoney Antibacterial Wound Gel
Trial: 17505376
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) group work
Trial: 14678367
Drug: Enhanced patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced patient participation in treatment choice
Trial: 14678367
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment protocol
Trial: 9238887
Drug: Oral-B toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B toothbrush
Trial: 2691573
Drug: Clovoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clovoxamine (50 mg b.d. to 300 mg max)
Trial: 2691573
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg b.d. to 30 mg max)
Trial: 1105692
Drug: Laminaria tents
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria tents inserted 14-18 hr before PGF2alpha infusion
Trial: 1105692
Drug: Laminaria tents
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria tents inserted at the same time as PGF2alpha infusion
Trial: 28246338
Drug: Reference book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference book providing weight‐based precalculated doses
Trial: 28246338
Drug: Card providing
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Card providing milligram‐per‐kilogram doses
Trial: 25521275
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection (1 µg) into tibialis anterior and erector spinae muscles and fasciae
Trial: 25521275
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection (1 µg)
Trial: 25521275
Drug: Acidic buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidic buffer injections (pH 4, 100 µl)
Trial: 20878159
Drug: Docetaxel/cisplatin (DP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/cisplatin (DP) as first-line treatment
Trial: 20878159
Drug: FOLFIRI as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI as first-line treatment
Trial: 20878159
Drug: FOLFIRI as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI as second-line treatment
Trial: 20878159
Drug: Docetaxel/cisplatin (DP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/cisplatin (DP) as second-line treatment
Trial: 19885944
Drug: Far-infrared rays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far-infrared rays (FIR) applied to three acupuncture points (Nei-Kuan (PC6), Shenmen (HT7), Sanyinjiao (SP6)) for 15 minutes twice a week for four weeks
Trial: 15277611
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg donepezil daily for 12 weeks
Trial: 15277611
Drug: Open-label donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label donepezil (5 mg daily for 6 weeks, then 10 mg daily for 6 weeks)
Trial: 8923850
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg, orally)
Trial: 1404449
Drug: Beta-carotene (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (0, 15, 30, 45, or 60 mg daily for approximately 9 months)
Trial: 3888229
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day of fish oil (Maxepa)
Trial: 3888229
Drug: 16 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g/day of fish oil (Maxepa)
Trial: 24097439
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (dual therapy)
Trial: 24739593
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (monotherapy)
Trial: 18854801
Drug: Natural plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural plant extracts for intimate hygiene (Salvia officinalis, Camomilla recutita, Thymus vulgaris) used once or twice a day for four weeks
Trial: 16317014
Drug: Early chemotherapy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early chemotherapy (MVP regimen: mitomycin C 8 mg/m2, vinblastine 6 mg/m2, cisplatin 50 mg/m2 or carboplatin AUC 5) every 3 weeks for up to six cycles
Trial: 16317014
Drug: Delayed chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed chemotherapy (initial best supportive care with chemotherapy added at time of symptomatic progression)
Trial: 16317014
Drug: Early chemotherapy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early chemotherapy (MVP regimen)
Trial: 8607237
Drug: Prostate-specific antigen
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate-specific antigen (PSA) measurement and digital rectal examination (DRE) followed by transrectal ultrasonography of the prostate when PSA or DRE is abnormal
Trial: 1750604
Drug: Inhaled nebulised
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulised fentanyl at 318 micrograms/ml
Trial: 1750604
Drug: Inhaled nebulised
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulised fentanyl at 159 micrograms/ml
Trial: 1750604
Drug: Inhaled nebulised
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulised fentanyl at 64 micrograms/ml
Trial: 7128188
Drug: Bromocriptine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (15 mg per day)
Trial: 7128188
Drug: Imipramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (75 mg per day)
Trial: 19488607
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg bid for 90 days)
Trial: 15832031
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of donepezil for 12 months
Trial: 9846856
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg Zn as ZnSO4 daily in fruit juice, Monday to Friday for 6 months)
Trial: 16823727
Drug: Insulin as
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin as part
Trial: 10688392
Drug: Penciclovir cream
RxNorm normalized name: Penciclovir
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penciclovir cream
Trial: 1500686
Drug: human lymphoblastoid
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: human lymphoblastoid interferon (ly‐IFN) at a dose of 5 MU/m2 i.m. three times a week for 6 months
Trial: 21690287
Drug: Oral oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oseltamivir
Trial: 27548898
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Treatment (PST)
Trial: 29794089
Drug: Interventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional therapy
Trial: 22548767
Drug: Omeprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (10 mg once daily)
Trial: 22548767
Drug: Famotidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (10 mg twice daily)
Trial: 22548767
Drug: Mosapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride (5 mg three times daily)
Trial: 22548767
Drug: Teprenone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprenone (50 mg three times daily)
Trial: 17274349
Drug: Continuous intervention
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intervention group (monthly educational campaign)
Trial: 19787608
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) injection 2.5 mg 3-5 days before operation
Trial: 19787608
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection before operation (noninjected group)
Trial: 15545877
Drug: Tc-99m-labeled antigranulocyte
RxNorm normalized name: Technetium Tc 99m-labeled red blood cells
DrugBank: Technetium Tc-99m red blood cells (DB09493)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc-99m-labeled antigranulocyte monoclonal antibody fragment Fab'2 (SMab, Leukoscan); 20 mCi (740 MBq) injected, scans obtained within 3 and 8 hours post-injection.
Trial: 11727205
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IGI)
Trial: 9450166
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) inhalation therapy (400 micrograms/day)
Trial: 9450166
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BDP inhalation therapy)
Trial: 29322434
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (NAC) 100 mg/kg bolus followed by intracoronary NAC 480 mg during PCI then intravenous NAC 10 mg/kg for 12 hours
Trial: 19860915
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (NAC)
Trial: 29322434
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (NAC) and control group
Trial: 26919554
Drug: Wraparound eyeglasses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wraparound eyeglasses in addition to medical treatment (group 1, n = 39)
Trial: 26919554
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (group 2, n = 31)
Trial: 23141813
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 70 mg every 2 weeks
Trial: 23141813
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 105 mg every 2 weeks
Trial: 23141813
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 140 mg every 2 weeks
Trial: 23141813
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 280 mg every 4 weeks
Trial: 23141813
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 350 mg every 4 weeks
Trial: 23141813
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 420 mg every 4 weeks
Trial: 26638010
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day
Trial: 20440092
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg prednisolone administered immediately after surgery
Trial: 20440092
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received Etorikoxib 120 mg 30 minutes before operation
Trial: 18305291
Drug: Double-blind antidepressant
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind antidepressant treatment
Trial: 12439162
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (0.51 mg/kg)
Trial: 12439162
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (1.41 mg/kg)
Trial: 2140489
Drug: Nicorandil 10
RxNorm normalized name: nicorandil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 10 mg
Trial: 415330
Drug: 0.75 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml/kg of 95% ethanol
Trial: 415330
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of delta9 tetrahydrocannabinol (THC)
Trial: 415330
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of delta9 tetrahydrocannabinol (THC)
Trial: 415330
Drug: 0.75 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml/kg of 95% ethanol together with 15 mg of THC
Trial: 31072317
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Dual Task (EMDT) in combination with usual care
Trial: 28125809
Drug: AmF/NaF/SnCl2 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF/NaF/SnCl2 solution twice a day
Trial: 28125809
Drug: AmF/NaF/SnCl2 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF/NaF/SnCl2 solution once a day
Trial: 28125809
Drug: NaF solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF solution (positive control, 500 ppm F‐, pH 4.5)
Trial: 31355775
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg
Trial: 25501988
Drug: Efavirenz 400
RxNorm normalized name: efavirenz 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 400 mg and 600 mg
Trial: 21875913
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel for 6 months
Trial: 17023769
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose 1 microg/kg in 10 minutes followed by an infusion rate of 0.2 microg/kg/hr)
Trial: 11127250
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin (PM) 12 mg/kg daily plus Sodium Stibogluconate (SB) 20 mg/kg daily for 21 days
Trial: 11127250
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin (PM) 18 mg/kg daily plus Sodium Stibogluconate (SB) 20 mg/kg daily for 21 days
Trial: 8474811
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula with 12.7 mg/L iron
Trial: 8474811
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula with 7.4 mg/L iron
Trial: 3082347
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg SCG aerosol
Trial: 3082347
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg SCG aerosol
Trial: 3082347
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg SCG aerosol
Trial: 3082347
Drug: Nebulised SCG
RxNorm normalized name: microcrystalline cellulose 102 SCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised SCG (10 g l‐1)
Trial: 30467952
Drug: Mildly increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly increased uACR (≥10 mg/g <30 mg/g)
Trial: 30467952
Drug: Mildly increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly increased uACR (≥10 mg/g <30 mg/g) in nonwhites
Trial: 27284115
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy using the frontal/executive program for about six months
Trial: 27284115
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy using the frontal/executive program
Trial: 24493413
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of delayed (123)I-MIBG scintigraphy and FMD
Trial: 20493957
Drug: Doxycycline (100mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100mg, twice daily)
Trial: 27317093
Drug: febuxostat (10-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: febuxostat (10-60 mg/day)
Trial: 27317093
Drug: non-pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-pharmacological treatment
Trial: 20206354
Drug: 200mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg of oral mifepristone followed 2 days later by 400 microg of sublingual misoprostol